

Several Measures to Support the High-Quality Development of Innovative Drugs

China – National Healthcare Security Administration, National Health Commission

Main information

Scope of Application:

Boost Innovative drugs in the Chinese Medical Insurance System, in R&D and in update of Listing and Procurement systems

Effective Date:

June 30th, 2025

Related Provisions:

- Basic Healthcare and Health Promotion Law
- Notice of the National Medical Security Administration on Further Promoting the Intelligent Review and Monitoring of Medical Security Funds [2023] No. 25
- Data Security Law

Pharm.east®

Key Topics

Framework

- Basic Healthcare and Health Promotion Law, Article 82: The expenses of basic medical services shall be mainly paid by the basic medical insurance fund and individuals. The State will raise basic medical insurance funds through multiple channels in accordance with the law, and gradually improve the mechanism for sustainable financing and adjustment of basic medical insurance coverage.
- Several provisions of the NHSA to coordinate the use of big data with the reforms of Basic Medical Insurance Funds

What's new

- **Use of national unified medical insurance information platform to collect and analyze data on disease spectra and clinical medication demand, develop data products tailored to innovative drug R&D needs**, and support pharmaceutical companies, research institutes, and medical institutions in rationally determining R&D directions and planning R&D pipelines, thereby improving innovation efficiency
- **Tailor BMI on Innovative Drugs, to let Innovative Drugs be included in BMI Drugs Lists**
- **Creation of Commercial Medical Insurance Innovative Drug List**

Sensitive Factors

- NHSA encourages commercial health insurance to expand investment in innovative drugs. **Potential concentration of Data Processing on Private Insurance Companies**
- Information related to public health are classified as **Important Data** according to Data Security Law and related provisions

Drivers

- **Interoperability:** conjugate data management, big data resources with pharma-economics and innovation in R&D
- **PPP – Partnership Public-Private:** Commercial Insurance Companies are involved in Innovation



HEALTH LAW ASIA

Shanghai - Bologna - Milan - Rome